Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib Continuation Study in AML, MDS, and CMML
NCT04842604Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of glasdegib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Pfizer. Started May 2021; status: completed.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04842604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842604.